Imclone Systems Incorporated
Records under this name other than patents Imclone Systems Incorporated holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Imclone Systems Incorporated
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,128,929 | ANTIBODIES AGAINST PDGFRa Formerly held In force · High confidence | In force | High confidence | |
| US 7,598,350 | Human Anti-Epidermal Growth Factor Receptor Antibody Formerly held In force · High confidence | In force | High confidence | |
| US 7,498,414 | Human antibodies specific to KDR and uses thereof Formerly held Term ended Term ended Jan 31, 2026 · From the USPTO record | Term ended | Term ended Jan 31, 2026 | From the USPTO record |
| US 8,057,791 | Human antibodies specific to KDR and uses thereof Formerly held Term ended Term ended Dec 7, 2023 · From the USPTO record | Term ended | Term ended Dec 7, 2023 | From the USPTO record |
| US 7,972,596 | Antibodies against vascular endothelial growth factor receptor-1 Formerly held Lapsed on the fee record Ended Jul 5, 2019 · From the USPTO record | Lapsed on the fee record | Ended Jul 5, 2019 | From the USPTO record |
| US 7,972,600 | Igf-Ir Antagonists as Adjuvants for Treatment of Prostate Cancer Formerly held Lapsed on the fee record Ended Jul 5, 2019 · High confidence | Lapsed on the fee record | Ended Jul 5, 2019 | High confidence |
| US 7,947,811 | Antibodies that bind specifically to human RON protein Formerly held Lapsed on the fee record Ended May 24, 2019 · From the USPTO record | Lapsed on the fee record | Ended May 24, 2019 | From the USPTO record |
| US 7,740,850 | PDGFRβ-specific antibodies Formerly held Lapsed on the fee record Ended Jun 22, 2018 · From the USPTO record | Lapsed on the fee record | Ended Jun 22, 2018 | From the USPTO record |
| US 6,852,533 | Purified populations of stem cells Term ended Term ended Jan 23, 2018 · From the USPTO record | Term ended | Term ended Jan 23, 2018 | From the USPTO record |
| US 8,623,604 | Methods for Predicting Responsiveness of a Cancer Cell to an ANTI-IGFR1 Antibody by Analysis of Mutations in PIK3CA Lapsed on the fee record Ended Jan 7, 2018 · High confidence | Lapsed on the fee record | Ended Jan 7, 2018 | High confidence |